Preferred Label : FLT3/KIT/VEGFR2/PDGFRB Inhibitor ETN101;
NCIt synonyms : FLT3/c-Kit/VEGFR2/PDGFR-beta Inhibitor ETN101; Kinase Inhibitor ETN101;
NCIt definition : An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like
tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), mast/stem cell factor receptor c-Kit
(SCFR; KIT), vascular endothelial growth factor receptor type 2 (VEGFR2) and platelet-derived
growth factor receptor beta (PDGFRB), with potential anti-angiogenic and antineoplastic
activities. Upon oral administration, FLT3/KIT/VEGFR2/PDGFRB inhibitor ETN101 targets,
binds to and inhibits the activity of FLT3, c-Kit, VEGFR2 and PDGFRB. This prevents
FLT3, c-Kit, VEGFR2 and PDGFRB-mediated signaling and the activation of downstream
signaling pathways. By inhibiting multiple RTKs, ETN101 may be able to inhibit angiogenesis
and tumor cell invasion, normalize abnormal blood vessels, and reverse the immunosuppressive
state of the tumor microenvironment (TME). This may halt tumor cell proliferation
in susceptible tumor cells. FLT3, c-Kit, VEGFR2, and PDGFRB are upregulated in a variety
of cancer cell types and play key roles in tumor cell proliferation, angiogenesis,
and metastasis.;
Molecule name : ETN-101; ETN 101;
Origin ID : C212936;
concept_is_in_subset
- has_target
